

- Sleeping sickness (human African trypanosomiasis) (*Cont.*):  
 treatment of, 1398, 1398t  
 eflornithine, 246e-8-9  
 melarsoprol, 246e-10  
 suramin, 246e-13
- Sleep paralysis, 188t, 189
- Sleep terrors, 192
- Sleep-wake cycle, 185-186, 185f
- Sleepwalking, 192
- SLGT2 (sodium-glucose co-transporter 2)  
 inhibitors, 2414t, 2415, 2416f
- Sliding filament model, for muscle contraction, 265e-5-6
- "Slip" (error), 12e-1
- Slipping clutch syndrome, 163
- Slow acetylators, 40
- Slow low-efficiency dialysis (SLED), 1811
- Slow reacting substance of anaphylaxis (SRSA), 372e-15t
- SLPI (secretory leukocyte protease inhibitor), 1223
- SMA (spinal muscle atrophy), 2631, 2634t, 2636
- SMAC, 102e-8-9
- SMAD4 gene mutations, 101e-1f, 101e-6t, 533
- SM-AHNMD (systemic mastocytosis associated with clonal hematologic non-mast cell lineage disease), 2120, 2120t
- Small airways disease. *See* Chronic obstructive pulmonary disease (COPD)
- Small intestine  
 absorption and secretion in, 626  
 benign tumors of, 536  
 bleeding from, 277  
 blood supply to, 1979, 1979f  
 double-balloon enteroscopy of, 1881, 1883f  
 endoscopy of, 1881. *See also* Capsule endoscopy  
 fluid volumes and electrolyte content of, 98e-4t  
 functions of, 1875, 1933  
 ischemia of. *See* Intestinal ischemia  
 length of, 1933  
 malignant tumors of, 536-537  
 motility of, 264-265  
 mucosal biopsy of, 1938-1940, 1940t, 1941f  
 neuroendocrine tumors of, 560t, 563, 567. *See also* Gastrointestinal neuroendocrine tumors (GI-NETs)  
 nutrient digestion and absorption in, 1933-1934  
 obstruction of, 103, 259, 1981. *See also* Intestinal obstruction  
 physiology of, 264-265, 264t  
 resection of, 96e-8
- Small-molecule inhibitors, 102e-9f, 102e-17
- Small noncleaved cell lymphoma. *See* Burkitt's lymphoma
- Smallpox  
 in bioterrorism, 261e-6  
 clinical features of, 131t, 261e-5t, 261e-6  
 diagnosis of, 261e-5t, 1185  
 differential diagnosis of, 134  
 eradication of, 8, 785  
 hemorrhagic, 261e-6  
 incidence pre- and postvaccine, U.S., 785t  
 malignant, 261e-6  
 prevention of, 261e-5t, 261e-7, 261e-7t  
 skin manifestations of, 25e-13f, 131t, 134, 261e-6, 829  
 treatment of, 261e-5t, 261e-6
- Smallpox vaccine, 352
- Small round cell tumor, desmoplastic, 101e-3t
- Small subunit rRNA (SSU rRNA) genes, 86e-2
- Small-vessel stroke, 2565, 2567f. *See also* Ischemic stroke
- "Smart pumps," 12e-2
- Smell. *See* Olfactory disorders; Olfactory system
- Smith-Lemli-Opitz syndrome, 2324t, 2354t
- SMO gene mutations, 500, 500f
- Smoke inhalation, 1692
- Smokeless tobacco, 237, 240t, 476, 502
- Smoking. *See also* Smoking cessation  
 cancer and, 2730, 2730t  
 bladder, 575  
 cervical, 594  
 colorectal, 539  
 esophageal, 475, 532-533  
 head and neck, 502  
 lung, 475, 506-507  
 oral, 237  
 pancreatic, 554  
 renal cell carcinoma, 578  
 skin, 500
- cardiovascular disease and, 2729-2730, 2730t  
 global considerations in, 266e-4  
 ischemic heart disease, 1587  
 peripheral artery disease, 1644  
 stroke risk, 2567t
- deaths related to, 2729
- drug interactions with, 2730, 2731t
- erectile dysfunction and, 326
- global considerations in, 17, 2729
- hemoglobin elevation and, 393
- IBD and, 1947
- in Leber hereditary optic neuropathy, 85e-9
- leukoplakia and, 240t
- of lower tar and nicotine cigarettes, 2731
- meningococcal infections and, 997
- neutrophil counts in, 418
- osteoporosis and, 2493
- passive exposure to  
 in children, 2730  
 COPD and, 1703  
 lung cancer and, 475, 506, 2730  
 respiratory disease and, 1662, 1693
- peptic ulcer disease and, 1917
- polycythemia in, 400
- in pregnancy, 2730, 2730t
- prevalence of, 2729
- prevention of, 2732
- respiratory disease and, 1662, 2730, 2730t  
 asthma, 1680  
 COPD, 1701, 1702, 1702f  
 interstitial lung diseases, 1713
- rheumatoid arthritis and, 2140, 2141
- second malignancy and, 477
- in women, 6e-5
- Smoking cessation, 2731  
 after lung cancer diagnosis, 506-507  
 in COPD, 1705  
 global considerations in, 17, 266e-4  
 in ischemic heart disease treatment, 1587  
 life expectancy increase following, 28t  
 in peripheral artery disease, 1644  
 pharmacologic therapy for, 507, 1705  
 physician intervention in, 2731-2732, 2731t  
 preoperative, 55t  
 stages of, 476  
 success rates of, 475  
 in thromboangiitis obliterans, 1646
- Smoothed gene, 387
- Smooth muscle, vascular  
 in atherosclerosis, 291e-2-3  
 calcium in, 265e-3-4, 265e-3f  
 contraction of, 265e-3-4, 265e-3f  
 control of cell tone, 265e-4  
 functions of, 265e-3-4  
 structure of, 265e-1f
- Smudge cells, 81e-2, 702, 702f
- Snakebites, 2733  
 clinical features of, 2733-2734, 2734f  
 complications of, 2738  
 epidemiology of, 2733  
 field management of, 2734-2735  
 global considerations in, 2738  
 hospital management of, 2735-2738, 2736-2737t  
 morbidity and mortality from, 2738  
 snake identification, 2733  
 wound infections following, 167e-2, 167e-3t
- Snellen chart, 195, 196f
- Snowshoe hare virus, 1309t
- SNPs. *See* Single-nucleotide polymorphisms (SNPs)
- SNRIs. *See* Serotonin norepinephrine reuptake inhibitors (SNRIs)
- SNRPN gene, 439, 2256
- SNRT (sinus node recovery time), 1469
- $S_{obs}$ , 86e-4
- Sochi virus, 1307t
- Social distancing, 917
- Social history, 1
- Social jet lag, 194
- Social justice, 5
- Social media, 17e-3
- Social phobia, 2712
- SOD1, 2633, 2635
- Sodium  
 blood pressure regulation and, 1612-1613  
 in cardiac contraction, 265e-6  
 in chronic kidney disease, 333e-3, 1814  
 fractional excretion of, 291t  
 hormonal regulation of, 332e-10-11, 332e-10f  
 intake, hypertension and, 1612  
 intestinal absorption of, 88  
 parenteral requirement for, 98e-5t  
 recommended intake of, 95e-2t  
 renal absorption/excretion of, 64e-2f, 296-297, 296f, 297f, 332e-3-6f, 332e-10-11, 332e-10f  
 in specialized nutritional support formulas, 98e-5  
 urine levels, in acute kidney injury, 291, 291t
- Sodium bicarbonate  
 for acidosis after cardiac arrest, 1769-1770, 1769f  
 adverse effects of, 1920  
 for alcohol-induced acidosis, 64e-9  
 for hyperkalemia, 312  
 for prevention of contrast-induced nephropathy, 1461  
 for uric acid nephropathy, 431e-5  
 for ventricular arrhythmias in overdose/ poisoning, 473e-8t, 473e-9t
- Sodium channels  
 cardiac, 273e-2, 273e-2f  
 muscle, disorders of, 462e-17-18, 462e-17f, 462e-17t  
 in seizure initiation, 2547
- Sodium citrate (Shohl's) solution, 64e-6, 318, 320
- Sodium current, in cardiac action potential, 273e-1f
- Sodium diarrhea, congenital, 268
- Sodium docusate, 62t
- Sodium ferric gluconate, 629
- Sodium-glucose co-transporter 2 (SLGT2)  
 inhibitors, 2414t, 2415, 2416f
- Sodium hippurate, 969
- Sodium hypochlorite  
 RSDL and, 262e-6  
 for staphylococcal skin infections, 345  
 for sulfur mustard exposure, 262e-4
- Sodium iodide, 2297
- Sodium iodide symporter (NIS), 372e-24t, 2284, 2284t
- Sodium ipodate, 2286t, 2297, 2300
- Sodium loading test, 2319
- Sodium modeling, in dialysis, 1822
- Sodium nitrite, 262e-7, 262e-8t
- Sodium phosphate enema, 62t
- Sodium polystyrene sulfonate (SPS), 312
- Sodium restriction  
 for ascites, 288  
 for hypertension, 1622t, 1623
- Sodium retention, 250, 251f
- Sodium stibogluconate, 246e-7, 1390, 1393
- Sodium sulfacetamide, 352
- Sodium thiosulfate, 262e-7, 262e-8t
- Sodium tyropanoate, 2286t
- Sodium valproate. *See* Valproate/valproic acid
- Sodoku (rat-bite fever), 129t, 167e-1-2
- Sofosbuvir, 215e-5t, 215e-6, 215e-10, 2047, 2049
- Soft (argasid) tick, 2745. *See also* Tick(s)
- Soft tissue, 827f
- Soft tissue infections. *See also* Cellulitis  
 actinomycotic, 1090  
 anaerobic bacterial, 1099  
 deep. *See* Myositis; Necrotizing fasciitis  
 enterococcal, 974